/**
 * DEPRECATED
 * Mock CSR business insights have been removed in Lumen Cortex consolidation.
 */

class CSRBusinessInsightsService {
  constructor() {
    throw new Error('[DEPRECATED] CSRBusinessInsightsService removed.');
  }

  initializeProtocolOptimizationInsights() {
    return {
      inclusionCriteriaOptimization: {
        insight: 'Studies with biomarker-driven inclusion criteria show 34% higher success rates',
        evidenceBase: 'Analysis of 156 oncology CSRs with molecular diagnostics',
        businessImpact: '$2.1M average savings per optimized study',
        recommendations: [
          'Implement PD-L1 expression ≥50% as primary inclusion criterion for immunotherapy trials',
          'Use TMB ≥10 mutations/Mb as secondary stratification factor',
          'Exclude patients with ECOG performance status >1 to improve safety profile',
        ],
        successRate: 89,
        confidenceLevel: 94,
      },

      doseSelectionGuidance: {
        insight:
          'Dose escalation studies with pharmacokinetic modeling reduce late-stage failures by 42%',
        evidenceBase: 'Meta-analysis of 78 Phase I/II CSRs with dose optimization',
        businessImpact: '$1.8M reduced development costs through optimal dose selection',
        recommendations: [
          'Implement model-based dose escalation instead of traditional 3+3 design',
          'Use exposure-response modeling to optimize therapeutic window',
          'Integrate biomarker-guided dosing for personalized medicine approaches',
        ],
        successRate: 76,
        confidenceLevel: 88,
      },

      endpointSelection: {
        insight: 'Studies with FDA-aligned primary endpoints have 67% higher approval rates',
        evidenceBase: 'Regulatory outcome analysis of 234 CSRs across therapeutic areas',
        businessImpact: '$3.2M faster time to market through optimized endpoint strategy',
        recommendations: [
          'Use overall survival as primary endpoint for oncology Phase III trials',
          'Implement progression-free survival with robust imaging assessment',
          'Include patient-reported outcomes as key secondary endpoints',
        ],
        successRate: 85,
        confidenceLevel: 92,
      },
    };
  }

  initializeRiskMitigationInsights() {
    return {
      safetySignalPrediction: {
        insight:
          'AI-powered safety analysis identifies 73% of serious adverse events before occurrence',
        evidenceBase: 'Machine learning analysis of 312 CSRs with safety outcome patterns',
        businessImpact: '$2.4M average cost avoidance through early safety detection',
        riskFactors: [
          'Hepatotoxicity signals in combination therapy protocols',
          'Cardiac events in patients with pre-existing cardiovascular conditions',
          'Immune-related adverse events in checkpoint inhibitor studies',
        ],
        mitigationStrategies: [
          'Implement enhanced liver function monitoring for combination therapies',
          'Use cardiac screening protocols for high-risk patient populations',
          'Establish immune-related adverse event management guidelines',
        ],
        accuracyRate: 73,
        confidenceLevel: 89,
      },

      recruitmentFeasibility: {
        insight: 'Site-specific recruitment modeling prevents 56% of enrollment delays',
        evidenceBase: 'Operational analysis of 189 CSRs with site performance metrics',
        businessImpact: '$1.6M saved per study through optimized recruitment strategy',
        predictiveFactors: [
          'Historical site performance in similar therapeutic areas',
          'Patient population density analysis by geography',
          'Competing trial landscape assessment',
        ],
        recommendations: [
          'Select sites with >80% historical enrollment success rate',
          'Implement patient pre-screening programs 3 months before study start',
          'Use digital recruitment strategies to expand patient reach',
        ],
        successRate: 82,
        confidenceLevel: 87,
      },

      regulatoryQueryPrediction: {
        insight:
          'Predictive modeling reduces FDA review cycles by 38% through proactive query prevention',
        evidenceBase: 'Regulatory interaction analysis of 267 CSRs with FDA correspondence',
        businessImpact: '$1.9M faster approval timeline through optimized regulatory strategy',
        commonQueries: [
          'Statistical analysis plan methodology clarifications',
          'Safety data presentation and interpretation',
          'Efficacy endpoint measurement and validation',
        ],
        preventionStrategies: [
          'Implement FDA guidance-aligned statistical methods',
          'Use standardized safety data presentation formats',
          'Provide comprehensive efficacy validation documentation',
        ],
        reductionRate: 38,
        confidenceLevel: 91,
      },
    };
  }

  initializeCompetitiveIntelligenceInsights() {
    return {
      competitorProtocolAnalysis: {
        insight:
          'Competitive protocol analysis reveals strategic advantages in 84% of market categories',
        evidenceBase: 'Cross-sponsor analysis of 445 CSRs across 13 therapeutic areas',
        businessImpact: '$2.8M market advantage through superior protocol design',
        competitiveAdvantages: [
          'Novel endpoint strategies providing regulatory differentiation',
          'Biomarker-driven patient selection improving success rates',
          'Innovative trial designs reducing development timelines',
        ],
        marketPositioning: [
          'First-in-class advantages through unique mechanism of action',
          'Best-in-class positioning through superior efficacy/safety profile',
          'Fast-follower strategies with improved patient convenience',
        ],
        successRate: 84,
        confidenceLevel: 93,
      },

      pricingStrategyOptimization: {
        insight: 'Efficacy-based pricing models increase peak sales potential by 28% on average',
        evidenceBase: 'Health economics analysis of 156 approved products with CSR efficacy data',
        businessImpact: '$45M increased peak sales through optimized pricing strategy',
        valueDeterminants: [
          'Comparative effectiveness versus standard of care',
          'Quality-adjusted life years (QALY) improvements',
          'Health system cost savings through reduced hospitalizations',
        ],
        pricingStrategies: [
          'Outcome-based pricing tied to clinical response rates',
          'Indication-specific pricing reflecting differential value',
          'Risk-sharing agreements with payers for expensive therapies',
        ],
        pricingPremium: 28,
        confidenceLevel: 86,
      },

      developmentPrioritization: {
        insight: 'Data-driven indication prioritization improves portfolio ROI by 45%',
        evidenceBase: 'Portfolio analysis of 89 multi-indication development programs',
        businessImpact: '$12M optimal resource allocation through strategic prioritization',
        prioritizationFactors: [
          'Unmet medical need severity and market size',
          'Competitive landscape intensity and differentiation potential',
          'Regulatory pathway complexity and approval probability',
        ],
        recommendations: [
          'Prioritize rare disease indications with orphan drug designation',
          'Focus on combination therapy strategies in crowded markets',
          'Leverage accelerated approval pathways for serious conditions',
        ],
        roiImprovement: 45,
        confidenceLevel: 89,
      },
    };
  }

  initializeRegulatoryStrategyInsights() {
    return {
      fdaFeedbackPatterns: {
        insight: 'FDA feedback pattern analysis improves approval probability by 52%',
        evidenceBase: 'Regulatory correspondence analysis of 178 successful approvals',
        businessImpact: '$2.7M faster approval through optimized regulatory strategy',
        keyPatterns: [
          'Early engagement with FDA through Type B meetings',
          'Comprehensive nonclinical safety package development',
          'Robust clinical pharmacology and dose optimization studies',
        ],
        successStrategies: [
          'Submit comprehensive briefing documents 60 days before meetings',
          'Use FDA-preferred statistical methods for primary analysis',
          'Implement risk evaluation and mitigation strategies proactively',
        ],
        approvalRate: 87,
        confidenceLevel: 94,
      },

      breakthroughDesignation: {
        insight:
          'Breakthrough therapy designation requests succeed 68% more often with optimal CSR evidence',
        evidenceBase: 'Breakthrough designation analysis of 67 successful applications',
        businessImpact: '$8M accelerated development timeline through breakthrough status',
        evidenceRequirements: [
          'Substantial improvement over existing therapy demonstrated',
          'Clinically meaningful endpoints with robust effect sizes',
          'Unmet medical need clearly documented with patient impact',
        ],
        applicationStrategies: [
          'Submit preliminary clinical data showing >50% response rate improvement',
          'Provide patient-reported outcome evidence of clinical benefit',
          'Include health economics data showing cost-effectiveness',
        ],
        designationRate: 68,
        confidenceLevel: 91,
      },

      submissionOptimization: {
        insight: 'Optimized submission packages reduce review timelines by 34% on average',
        evidenceBase: 'Submission quality analysis of 234 NDA/BLA applications',
        businessImpact: '$3.1M faster market access through streamlined review process',
        optimizationFactors: [
          'Common Technical Document (CTD) format compliance',
          'Electronic submission standards adherence',
          'Proactive quality control and data integrity measures',
        ],
        bestPractices: [
          'Use eCTD format with proper hyperlinks and navigation',
          'Implement robust data integrity and audit trail documentation',
          'Provide comprehensive clinical study reports with clear narratives',
        ],
        timelineReduction: 34,
        confidenceLevel: 88,
      },
    };
  }

  initializeClientSuccessMetrics() {
    return {
      biotechStartup: {
        clientType: 'Biotech Startup',
        studyPhase: 'Phase II Oncology',
        businessImpact: {
          costSavings: 2300000,
          timelineSavings: 5.2,
          roiMultiplier: 9.4,
        },
        keyAchievements: [
          'Optimized inclusion criteria reducing screen failure rate by 45%',
          'Identified optimal dose reducing late-stage toxicity by 38%',
          'Improved endpoint strategy increasing regulatory acceptance by 67%',
        ],
        clientTestimonial:
          'CSR Intelligence helped us optimize our Phase II oncology protocol, saving $2.3M and 5 months in development time.',
      },

      midSizePharma: {
        clientType: 'Mid-Size Pharmaceutical',
        studyPhase: 'Phase III Cardiovascular',
        businessImpact: {
          costSavings: 4800000,
          timelineSavings: 6.8,
          roiMultiplier: 12.1,
        },
        keyAchievements: [
          'Predictive risk assessment prevented 6-month recruitment delay',
          'Safety signal detection avoided late-stage safety issues',
          'Regulatory strategy optimization improved approval probability by 42%',
        ],
        clientTestimonial:
          'Predictive risk assessment identified recruitment issues early, preventing a 6-month delay in our cardiovascular study.',
      },

      largePharma: {
        clientType: 'Large Pharmaceutical',
        studyPhase: 'Multi-Indication Portfolio',
        businessImpact: {
          costSavings: 18000000,
          timelineSavings: 14.5,
          roiMultiplier: 15.6,
        },
        keyAchievements: [
          'Competitive intelligence improved market positioning by 25%',
          'Portfolio optimization increased development efficiency by 33%',
          'Regulatory strategy reduced review cycles across multiple programs',
        ],
        clientTestimonial:
          'Competitive intelligence insights helped us position our immunology drug strategically, increasing peak sales projection by 25%.',
      },
    };
  }

  // High-value use case methods
  getProtocolOptimizationInsights() {
    return {
      category: 'Protocol Design Optimization',
      businessValue: '$2.1M average savings per study',
      timelineSavings: '4.2 months faster development',
      successRate: '89% protocol optimization success rate',
      insights: this.protocolOptimizationInsights,
      clientImpact: this.clientSuccessMetrics.biotechStartup,
    };
  }

  getRiskMitigationInsights() {
    return {
      category: 'Predictive Risk Assessment',
      businessValue: '$2.4M average risk avoidance per study',
      timelineSavings: '2.8 months delay prevention',
      successRate: '82% risk mitigation success rate',
      insights: this.riskMitigationInsights,
      clientImpact: this.clientSuccessMetrics.midSizePharma,
    };
  }

  getCompetitiveIntelligenceInsights() {
    return {
      category: 'Competitive Intelligence',
      businessValue: '$2.8M market advantage per indication',
      timelineSavings: '3.1 months strategic advantage',
      successRate: '84% competitive positioning success',
      insights: this.competitiveIntelligenceInsights,
      clientImpact: this.clientSuccessMetrics.largePharma,
    };
  }

  getRegulatoryStrategyInsights() {
    return {
      category: 'Regulatory Strategy Intelligence',
      businessValue: '$2.7M faster approval pathway',
      timelineSavings: '6.2 months regulatory advantage',
      successRate: '87% regulatory success rate',
      insights: this.regulatoryStrategyInsights,
      clientImpact: this.clientSuccessMetrics.largePharma,
    };
  }

  // Main method to get all high-value use cases
  getAllHighValueUseCases() {
    return {
      protocolOptimization: this.getProtocolOptimizationInsights(),
      riskMitigation: this.getRiskMitigationInsights(),
      competitiveIntelligence: this.getCompetitiveIntelligenceInsights(),
      regulatoryStrategy: this.getRegulatoryStrategyInsights(),
      totalBusinessImpact: {
        combinedSavings: 10000000, // $10M total potential savings
        timelineReduction: 16.3, // months
        portfolioROI: 15.6, // 15.6x return on investment
        clientSatisfaction: 94, // % satisfaction rate
      },
    };
  }

  // Method to get specific use case insights
  getUseCaseInsights(useCaseId) {
    switch (useCaseId) {
      case 'protocol-optimization':
        return this.getProtocolOptimizationInsights();
      case 'risk-mitigation':
        return this.getRiskMitigationInsights();
      case 'competitive-intelligence':
        return this.getCompetitiveIntelligenceInsights();
      case 'regulatory-strategy':
        return this.getRegulatoryStrategyInsights();
      default:
        return this.getAllHighValueUseCases();
    }
  }
}

// Create singleton instance
export default {};
